Optum

Dermatology Enrollment Form

Optum Specialty Phone: 855-427-4682 | Optum Specialty Fax: 877-342-4596

Specialty Pharmacy Enrollment Form

Please detach before submitting to a pharmacy – tear here

This form is not a valid prescription in Arizona

PATIENT INFORMATION

Please complete the following or send patient demographic sheet

Patient Name _____
Address _____
Address 2 _____
City, State, Zip _____
Home Phone _____ Alternate Phone _____
DOB _____ Last Four of SS# _____ Gender _____
Language Preference: ☐ English ☐ Spanish ☐ Other _____

PRESCRIBER INFORMATION

Prescriber's Name _____
DEA _____
NPI _____
Group/Hospital _____
Address _____
City, State, ZIP _____
Phone _____ Fax _____
Contact Person _____ Phone _____

INSURANCE INFORMATION (Must fax a copy of patient's insurance card including both sides)

Prior Authorization Reference number: _____

MEDICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed)

Diagnosis – Please include diagnosis name with ICD-10 code

☐ L20 Atopic dermatitis
☐ L28.1 Prurigo nodularis
☐ L40.0 Psoriasis vulgaris
☐ L40.2 Acrodermatitis continua
☐ L40.4 Guttate psoriasis
☐ L40.1 Generalized pustular psoriasis
☐ L40.3 Pustulosis palmaris et plantaris
☐ L40.54 Psoriatic juvenile arthropathy
☐ L40.59 Other psoriatic arthropathy
☐ L73.2 Hidradenitis suppurativa
☐ L40.8 Other psoriasis _____
☐ Other Diagnosis: ICD-10 Code _____ Description _____

Date of Diagnosis _____
Has a TB test been performed? ☐ Yes ☐ No
Does the patient have an active infection? ☐ Yes ☐ No

Start Date _____ **Review Date** _____

Additional Information Therapy: ☐ New ☐ Reauthorization ☐ Restart

Weight _____ kg/lbs Height _____ cm/in
Allergies _____
Lab Data _____
Prior Therapies _____
Concomitant Medications _____
_____
Additional Comments _____
_____

Injection Training Required: ☐ Yes ☐ No

PRESCRIPTION INFORMATION

Medication	Strength	Dose & Directions	Qty/Refills
☐ Adbry™	150 mg/mL prefilled syringe	Induction Dose: Inject SC four 150 mg injections on Day 1, followed by two 150 mg injections every other week. Maintenance Dose: ☐ Inject SC two 150 mg injections every other week. ☐ Inject SC two 150 mg injections every four weeks. Consideration if body weight is below 100 kg, and completed 16 weeks of treatment.	Quantity:_____ Refills: _____
☐ Amjevita ™	☐ 40 mg/0.8 mL Prefilled Syringe (citrate-free) ☐ 40 mg/0.8 mL Prefilled SureClick® autoinjector (citrate-free) ☐ Other _____	☐ Psoriasis Induction Dose: Inject 80 mg SC on day 1, followed by 40 mg SC on day 8, then 40 mg every other week ☐ Psoriasis/Psoriatic Arthritis Maintenance Dose: Inject 40mg SC every other week. ☐ Other_____	Quantity:_____ Refills: _____
☐ Avsola®	100 mg Vial	☐ Induction Dose: Infuse 5 mg/kg (Dose = ____mg) IV at week 0, week 2, week 6 and every 8 weeks thereafter (0 refills). ☐ Maintenance Dose: Infuse 5 mg/kg (Dose = ____mg) IV every 8 weeks. ☐ Other: _____	Quantity:_____ # of 100 mg vial Refills: _____
☐ Cibinqo™	☐ 50 mg tablet ☐ 100 mg tablet ☐ 200 mg tablet		Quantity:_____ Refills: _____
☐ Cimzia®	Cimzia Starter Kit (6 prefilled syringes)	☐ Loading Dose: Inject 400mg SC (2 prefilled syringes) initially and at weeks 2 and 4.	Quantity: 1 Kit Refills: 0
☐ Cimzia®	☐ 200 mg/1 mL Prefilled Syringe ☐ 200 mg Vial	Psoriasis Maintenance Dose: ☐ 400 mg (given as 2 SC of 200 mg each) every other week. ☐ 200 mg SC every other week. Psoriatic Arthritis Maintenance Dose: ☐ 200 mg SC every other week. ☐ 400 mg (given as 2 SC of 200 mg each) every 4 weeks. ☐ Other: _____	Quantity:_____ Refills: _____
☐ Cosentyx®	☐ Sensoready® pen 150 mg/mL injection ☐ Prefilled syringe 150 mg/mL injection	☐ Psoriasis Loading Dose: Inject 300 mg (two injections) SC at weeks 0, 1, 2, 3 and 4 (0 refills). ☐ Psoriasis Maintenance Dose: Inject 300 mg (two injections) SC every 4 weeks. ☐ Psoriatic Arthritis Loading Dose: (if needed): 150 mg SC at weeks 0,1,2,3, and 4 (0 refills). ☐ Psoriatic Arthritis Maintenance Dose: 150mg SC every 4 weeks. ☐ Other: _____	Quantity:_____ Refills: _____

*Prescriber Authorization: I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Ship to: ☐ Patient ☐ Office ☐ Other _____ Date _____ Needs by Date _____

☐ Product Substitution permitted ☐ Dispense as Written

Prescriber's Signature _____ Date _____

Supervising Physician Signature: _____ Date _____

Electronic or digital signatures not accepted.

Optum

Dermatology Enrollment Form

Optum Specialty Phone: 855-427-4682 | Optum Specialty Fax: 877-342-4596

Specialty Pharmacy Enrollment Form

Please detach before submitting to a pharmacy - tear here

This form is not a valid prescription in Arizona

PATIENT INFORMATION

Please complete the following or send patient demographic sheet

Patient Name _____

Address _____

Address 2 _____

City, State, Zip _____

Home Phone _____ Alternate Phone _____

DOB _____ Last Four of SS# _____ Gender _____

Language Preference: ☐ English ☐ Spanish ☐ Other _____

PRESCRIBER INFORMATION

Prescriber's Name _____

DEA _____

NPI _____

Group/Hospital _____

Address _____

City, State, ZIP _____

Phone _____ Fax _____

Contact Person _____ Phone _____

INSURANCE INFORMATION (Must fax a copy of patient's insurance card including both sides)

Prior Authorization Reference number: _____

MEDICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed)

Diagnosis – Please include diagnosis name with ICD-10 code

☐ L40.0 Psoriasis vulgaris
☐ L40.1 Generalized pustular psoriasis
☐ L40.2 Acrodermatitis continua
☐ L40.3 Pustulosis palmaris et plantaris
☐ L40.4 Guttate psoriasis
☐ L40.54 Psoriatic juvenile arthropathy
☐ L40.59 Other psoriatic arthropathy
☐ L73.2 Hidradenitis suppurativa
☐ L40.8 Other psoriasis _____
☐ Other Diagnosis: ICD-10 Code _____ Description _____

Date of Diagnosis _____

Has a TB test been performed? ☐ Yes ☐ No

Does the patient have an active infection? ☐ Yes ☐ No

Start Date _____ **Review Date** _____

Additional Information Therapy: ☐ New ☐ Reauthorization ☐ Restart

Weight _____ kg/lbs Height _____ cm/in

Allergies _____

Lab Data _____

Prior Therapies _____

Concomitant Medications _____

Additional Comments _____

Injection Training Required: ☐ Yes ☐ No

PRESCRIPTION INFORMATION

☐ Dupixent®	☐ 300mg/2ml Prefilled Pen ☐ 300mg/2mL Prefilled Syringe ☐ 200mg/1.14mL Prefilled Syringe	Adults with Atopic Dermatitis or Prurigo Nodularis: ☐ 600 mg (two 300 mg injections) followed by 300 mg Q2W Pediatric Patients with Atopic Dermatitis: **Body Weight** / **Initial Dose** / **Subsequent Doses** ☐ 15 to less than 30 kg — 600 mg (two 300 mg injections) — 300 mg Q4W ☐ 30 to less than 60 kg — 400 mg (two 200 mg injections) — 200 mg Q2W ☐ 60 kg or more — 600 mg (two 300 mg injections) — 300 mg Q2W	Quantity: _____ Refills: _____
☐ Enbrel®	☐ 50 mg/mL Sureclick™ Autoinjector ☐ 50 mg/mL Prefilled Syringe ☐ 50 mg/mL Enbrel Mini™ prefilled cartridge for use with the AutoTouch™ reusable autoinjector only (Prescriber MUST supply). Avella/Briova does not order the autoinjector. ☐ 25 mg/0.5 mL Prefilled Syringe ☐ 25mg/0.5ml single-dose vial	☐ Psoriasis Induction Dose: Inject 50 mg SC TWICE a week (3 to 4 days apart) for 3 months, then maintenance dosing (8 pens, 2 refills). ☐ Psoriasis Maintenance Dose: Inject 50 mg SC ONCE a week. ☐ Psoriatic Arthritis Dose: Inject 50 mg SC ONCE a week. ☐ Other: _____	Quantity: _____ Refills: _____
☐ Humira®	☐ Psoriasis 80 mg/0.8 mL and 40 mg/0.4 mL Starter Package **Citrate Free**	☐ Psoriasis Induction Dose: Inject 80 mg SC on day 1, followed by 40 mg SC on day 8, then 40 mg every other week.	Quantity: 1 Package Refills: 0
☐ Humira®	☐ Hidradenitis Suppurativa 80 mg/0.8 mL Starter Package **Citrate Free**	☐ Hidradenitis Suppurativa Induction Dose: Inject SC 160mg Day 1, then 80mg two weeks later (Day 15), then 40mg on Day 29 and subsequent doses.	Quantity: 1 Package Refills: 0
☐ Humira®	☐ 40 mg/0.4 mL Pen **Citrate Free** ☐ 40 mg/0.4 mL Prefilled Syringe **Citrate Free** ☐ Other: _____	☐ Psoriasis/Psoriatic Arthritis Maintenance Dose: Inject 40mg SC every other week. ☐ Hidradenitis Suppurativa Maintenance Dose: Inject 40 mg SC every week. ☐ Other: _____	Quantity: _____ Refills: _____
☐ Ilumya™	100 mg/mL Prefilled Syringe	☐ Psoriasis Induction Dose: Inject one pre-filled syringe (100 mg) SC at weeks 0 and 4, then maintenance dosing (2 syringes, no refills). ☐ Psoriasis Maintenance Dose: Inject one pre-filled syringe (100 mg) SC every 12 weeks. ☐ Other: _____	Quantity: _____ Refills: _____

***Prescriber Authorization:** I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Ship to: ☐ Patient ☐ Office ☐ Other _____ Date _____ Needs by Date _____

☐ Product Substitution permitted ☐ Dispense as Written

Prescriber's Signature _____ Date _____

Supervising Physician Signature: _____ Date _____

Electronic or digital signatures not accepted.

Optum

Dermatology Enrollment Form

Optum Specialty Phone: 855-427-4682 | Optum Specialty Fax: 877-342-4596

Specialty Pharmacy Enrollment Form

Please detach before submitting to a pharmacy - tear here

This form is not a valid prescription in Arizona

PATIENT INFORMATION

Please complete the following or send patient demographic sheet

Patient Name _____

Address _____

Address 2 _____

City, State, Zip _____

Home Phone _____ Alternate Phone _____

DOB _____ Last Four of SS# _____ Gender _____

Language Preference: ☐ English ☐ Spanish ☐ Other _____

PRESCRIBER INFORMATION

Prescriber's Name _____

DEA _____

NPI _____

Group/Hospital _____

Address _____

City, State, ZIP _____

Phone _____ Fax _____

Contact Person _____ Phone _____

INSURANCE INFORMATION (Must fax a copy of patient's insurance card including both sides)

Prior Authorization Reference number: _____

MEDICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed)

Diagnosis – Please include diagnosis name with ICD-10 code

☐ L20 Atopic dermatitis
☐ L40.0 Psoriasis vulgaris
☐ L40.2 Acrodermatitis continua
☐ L40.4 Guttate psoriasis
☐ L40.59 Other psoriatic arthropathy
☐ L40.8 Other psoriasis _____
☐ L40.1 Generalized pustular psoriasis
☐ L40.3 Pustulosis palmaris et plantaris
☐ L40.54 Psoriatic juvenile arthropathy
☐ L73.2 Hidradenitis suppurativa
☐ Other Diagnosis: ICD-10 Code _____ Description _____

Date of Diagnosis _____

Has a TB test been performed? ☐ Yes ☐ No

Does the patient have an active infection? ☐ Yes ☐ No

Start Date _____ **Review Date** _____

Additional Information Therapy: ☐ New ☐ Reauthorization ☐ Restart

Weight _____ kg/lbs Height _____ cm/in

Allergies _____

Lab Data _____

Prior Therapies _____

Concomitant Medications _____

Additional Comments _____

Injection Training Required: ☐ Yes ☐ No

PRESCRIPTION INFORMATION

☐ Inflectra®	100 mg vial	☐ Induction Dose: Infuse 5 mg/kg (Dose = ____mg) IV at week 0, week 2, week 6 and every 8 weeks thereafter. ☐ Maintenance Dose: Infuse at 5 mg/kg (Dose = ____mg) IV every 8 weeks. ☐ Other: _____	Quantity:_____ # of 100 mg vial Refills: _____
☐ Orencia®	☐ 125 mg/mL Prefilled Syringe ☐ 125mg/ml ClickJect Autoinjector ☐ 250 mg vial ☐ Other: _____	Inject 125 mg SC once weekly. ☐ Other: _____	Quantity:_____ Refills: _____
☐ Otezla®	Titration Starter Pack	Day 1: 10 mg PO in the morning. Day 2: 10 mg PO in the morning and 10 mg PO in the evening. Day 3: 10 mg PO in the morning and 20 mg PO in the evening. Day 4: 20 mg PO in the morning and 20 mg PO in the evening. Day 5: 20 mg PO in the morning and 30 mg PO in the evening. Day 6 and thereafter: 30 mg PO twice daily.	Quantity: 1 Pack Refills: 0
☐ Otezla®	30 mg tablet	☐ Maintenance Dose: 30 mg tablet PO twice daily. ☐ Other: _____	Quantity:_____ Refills: _____
☐ Remicade®	100 mg Vial	☐ Induction Dose: Infuse 5 mg/kg (Dose = ____mg) IV at week 0, week 2, week 6 and every 8 weeks thereafter (0 refills). ☐ Maintenance Dose: Infuse 5 mg/kg (Dose = ____mg) IV every 8 weeks. ☐ Other: _____	Quantity:_____ # of 100 mg vial Refills: _____
☐ Renflexis®	100 mg Vial	☐ Induction Dose: Infuse 5 mg/kg (Dose = ____mg) IV at week 0, week 2, week 6 and every 8 weeks thereafter (0 refills). ☐ Maintenance Dose: Infuse 5 mg/kg (Dose = ____mg) IV every 8 weeks. ☐ Other: _____	Quantity:_____ # of 100 mg vial Refills: _____
☐ Rinvoq®	☐ 15 mg tablet-Maintenance Dose ☐ 30 mg table-Maintenance Dose	☐ Maintenance Dose: Take 15 mg PO once daily ☐ Alternative Maintenance Dose: Take 30 mg PO once daily	Quantity:_____ Refills: _____

***Prescriber Authorization:** I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Ship to: ☐ Patient ☐ Office ☐ Other _____ Date _____ Needs by Date _____

☐ Product Substitution permitted ☐ Dispense as Written

Prescriber's Signature _____ Date _____

Supervising Physician Signature: _____ Date _____

Electronic or digital signatures not accepted.

Optum

Dermatology Enrollment Form

Optum Specialty Phone: 855-427-4682 | Optum Specialty Fax: 877-342-4596

Specialty Pharmacy Enrollment Form

Please detach before submitting to a pharmacy - tear here

This form is not a valid prescription in Arizona

PATIENT INFORMATION

Please complete the following or send patient demographic sheet

Patient Name _____

Address _____

Address 2 _____

City, State, Zip _____

Home Phone _____ Alternate Phone _____

DOB _____ Last Four of SS# _____ Gender _____

Language Preference: ☐ English ☐ Spanish ☐ Other _____

PRESCRIBER INFORMATION

Prescriber's Name _____

DEA _____

NPI _____

Group/Hospital _____

Address _____

City, State, ZIP _____

Phone _____ Fax _____

Contact Person _____ Phone _____

INSURANCE INFORMATION (Must fax a copy of patient's insurance card including both sides)

Prior Authorization Reference number: _____

MEDICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed)

Diagnosis – Please include diagnosis name with ICD-10 code

☐ L40.0 Psoriasis vulgaris
☐ L40.1 Generalized pustular psoriasis
☐ L40.2 Acrodermatitis continua
☐ L40.3 Pustulosis palmaris et plantaris
☐ L40.4 Guttate psoriasis
☐ L40.54 Psoriatic juvenile arthropathy
☐ L40.59 Other psoriatic arthropathy
☐ L73.2 Hidradenitis suppurativa
☐ L40.8 Other psoriasis _____
☐ Other Diagnosis: ICD-10 Code _____

Description _____

Date of Diagnosis _____

Has a TB test been performed? ☐ Yes ☐ No

Does the patient have an active infection? ☐ Yes ☐ No

Start Date _____ **Review Date** _____

Additional Information Therapy: ☐ New ☐ Reauthorization ☐ Restart

Weight _____ kg/lbs Height _____ cm/in

Allergies _____

Lab Data _____

Prior Therapies _____

Concomitant Medications _____

Additional Comments _____

Injection Training Required: ☐ Yes ☐ No

PRESCRIPTION INFORMATION

☐ Siliq®	☐ 210 mg/1.5 mL single-dose prefilled syringe	Inject one prefilled syringe (210 mg) SC at weeks 0, 1 and 2, followed by one prefilled syringe (210 mg) every 2 weeks. Prescribers must be certified in the SILIQ REMS Program to prescribe SILIQ. Please visit the following REMS website to register before prescribing SILIQ: SILIQ REMS Website (https://siliqrems.com/SiliqUI/home.u)	Quantity:_____ Refills: _____
☐ Simponi®	☐ 50 mg/0.5 mL SmartJect® Autoinjector ☐ 50 mg/0.5 mL Prefilled Syringe	☐ Psoriatic Arthritis Dose: Inject 50 mg SC once a month. ☐ Other: _____	Quantity:_____ Refills: _____
☐ Simponi Aria®	50 mg/4 mL in a single-dose vial	Psoriatic Arthritis Dosing: ☐ Induction Dose: 2 mg/kg IV infusion over 30 minutes at weeks 0 and 4, then every 8 weeks thereafter (0 refills). ☐ Maintenance Dose: 2 mg/kg IV infusion over 30 minutes every 8 weeks.	Quantity:_____ # of 50 mg vial Refills: _____
☐ Skyrizi®	☐ 150 mg/mL prefilled syringe ☐ 150 mg/mL prefilled pen	☐ Psoriasis Induction Dose: Inject 150 mg SC at Weeks 0 and 4, then maintenance dosing (0 refills). ☐ Psoriasis Maintenance Dose: Inject 150mg SC every 12 weeks. ☐ Other: _____	Quantity:_____ Refills: _____
☐ Sotyktu™	6 mg tablet	☐ Take one 6 mg tablet PO once daily. ☐ Other: _____	Quantity:_____ Refills: _____
☐ Stelara®	☐ 45 mg/0.5 mL prefilled syringe ☐ 90 mg/mL prefilled syringe	☐ For patients weighing ≤100 kg (220 lbs): Inject 45 mg SC initially and 4 weeks later (2 syringes, 0 refills). ☐ For patients weighing >100 kg (220 lbs): Inject 90 mg SC initially and 4 weeks later (2 syringes, 0 refills). ☐ Maintenance Dose: Inject 45mg SC every 12 weeks. ☐ Maintenance Dose: Inject 90mg SC every 12 weeks. ☐ Other: _____	Quantity:_____ Refills: _____

***Prescriber Authorization:** I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Ship to: ☐ Patient ☐ Office ☐ Other _____ Date _____ Needs by Date _____

☐ Product Substitution permitted ☐ Dispense as Written

Prescriber's Signature _____ Date _____

Supervising Physician Signature: _____ Date _____

Electronic or digital signatures not accepted.

Optum

Dermatology Enrollment Form

Optum Specialty Phone: 855-427-4682 | Optum Specialty Fax: 877-342-4596

Specialty Pharmacy Enrollment Form

Please detach before submitting to a pharmacy - tear here

This form is not a valid prescription in Arizona

PATIENT INFORMATION

Please complete the following or send patient demographic sheet

Patient Name _____

Address _____

Address 2 _____

City, State, Zip _____

Home Phone _____ Alternate Phone _____

DOB _____ Last Four of SS# _____ Gender _____

Language Preference: ☐ English ☐ Spanish ☐ Other _____

PRESCRIBER INFORMATION

Prescriber's Name _____

DEA _____

NPI _____

Group/Hospital _____

Address _____

City, State, ZIP _____

Phone _____ Fax _____

Contact Person _____ Phone _____

INSURANCE INFORMATION (Must fax a copy of patient's insurance card including both sides)

Prior Authorization Reference number: _____

MEDICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed)

Diagnosis – Please include diagnosis name with ICD-10 code

☐ L40.0 Psoriasis vulgaris
☐ L40.1 Generalized pustular psoriasis
☐ L40.2 Acrodermatitis continua
☐ L40.3 Pustulosis palmaris et plantaris
☐ L40.4 Guttate psoriasis
☐ L40.54 Psoriatic juvenile arthropathy
☐ L40.59 Other psoriatic arthropathy
☐ L73.2 Hidradenitis suppurativa
☐ L40.8 Other psoriasis _____
☐ Other Diagnosis: ICD-10 Code _____

Description _____

Date of Diagnosis _____

Has a TB test been performed? ☐ Yes ☐ No

Does the patient have an active infection? ☐ Yes ☐ No

Start Date _____ **Review Date** _____

Additional Information Therapy: ☐ New ☐ Reauthorization ☐ Restart

Weight _____ kg/lbs Height _____ cm/in

Allergies _____

Lab Data _____

Prior Therapies _____

Concomitant Medications _____

Additional Comments _____

Injection Training Required: ☐ Yes ☐ No

PRESCRIPTION INFORMATION

☐ Taltz®	☐ 80 mg Single Dose Autoinjector ☐ 80 mg Single Dose Prefilled Syringe	Psoriasis Induction Dosing: ☐ Starting Dose: Inject SC two 80 mg injections on Day 1, then begin first induction dose 2 weeks later. ☐ Induction Dose: Inject SC one 80 mg injection every 2 weeks (weeks 2-10). ☐ Final Induction Dose: Inject SC one 80 mg injection (week 12). Psoriatic Arthritis Induction Dosing: ☐ Induction Dose: 160mg SC at week 0. ☐ Maintenance Dose: 80mg SC once every 4 weeks.	☐ 8 pens/syringes ☐ 2 pens/syringes Quantity: _____ Refills: _____
☐ Tremfya®	☐ 100 mg/mL prefilled syringe ☐ 100 mg/ml One-Press Injector	☐ Induction Dose: Inject 100mg SC at week 0 and week 4 (2 syringes/pens, 0 refills). ☐ Maintenance Dose: Inject 100mg SC once every 8 weeks.	Quantity: _____ Refills: _____
☐ Xeljanz®	☐ 5 mg Tablet ☐ 11 mg XR Tablet	☐ Take one 5 mg tablet PO twice daily. ☐ Take one 11 mg tablet PO once daily. ☐ Other: _____	Quantity: _____ Refills: _____
☐ Other	☐ Other: _____	☐ Other: _____	Quantity: _____ Refills: _____

***Prescriber Authorization:** I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

Ship to: ☐ Patient ☐ Office ☐ Other _____ Date _____ Needs by Date _____

☐ Product Substitution permitted ☐ Dispense as Written

Prescriber's Signature _____ Date _____

Supervising Physician Signature: _____ Date _____

Electronic or digital signatures not accepted.